Studies have shown that in invasive breast cancers accompanied by PD, hormone receptor positivity is lower and HER2 positivity is 2 to 4 times higher than invasive cancers without PD [2,4,9,10]. This evidence concerns the gene NR4A1 and invasive breast carcinoma.